Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Return to Table of Contents

Table 2b. Recommendations for coadministering antiretroviral drugs with rifampin in children – 2013

Antiretroviral drug regimen choices*

Recommended change in dose of antiretroviral drug

Recommended change in dose of rifampin

Comments

“Super-boosted” lopinavir / ritonavir
+ 2 NRTIs

Pediatric weight-adjusted dosing for lopinavir/ritonavir* (Kaletra™)PLUSadded ritonavir to reach mg to mg parity of lopinavir and ritonavir doses

No change

Preferred.

Zidovudine/lamivudine/abacavir

None
(standard pediatric weight-adjusted dosing*)

No change

Alternative for children <3 years

Efavirenz + 2 NRTIs

None
(standard pediatric weight-adjusted dosing*)

No change

Efavirenz AUC ↓ by 20-30% on average, though effect is highly variable.

Alternative for children age >3 years.

Careful monitoring of virologic response; therapeutic drug monitoring of efavirenz levels if available

 

* For pediatric dosing see: Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1-268. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.

Top